Does Cosentyx Increase IBD Risk?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, carries warnings for new-onset or worsening inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.[1][2] Clinical trials and post-marketing data show rare cases of IBD onset or exacerbation, leading to its black box warning in the U.S. label.[3] The risk appears low—less than 1% in trials—but real-world use has prompted monitoring recommendations.
What Do Clinical Trials Show?
In phase 3 trials for plaque psoriasis (ERASURE/FIXTURE) and psoriatic arthritis (FUTURE studies), IBD events were infrequent: 0.1-0.4% for secukinumab vs. 0% for placebo.[4] A 5-year extension study reported 0.5% incidence of ulcerative colitis or Crohn's-like symptoms.[5] No dose-response pattern emerged, but patients with prior IBD history were excluded, limiting data on that group.
Real-World Evidence and Case Reports
Post-approval surveillance via FDA's FAERS database identified over 100 IBD reports by 2020, some severe enough for discontinuation or colectomy.[6] A 2022 Swedish registry study of 3,000+ psoriasis patients found no overall IBD risk increase with secukinumab vs. other biologics, but a signal for Crohn's flares in those with baseline gut issues.[7] European Medicines Agency reviews confirmed rare IBD onset, often within months of starting therapy.[8]
Why Might It Happen? Mechanism Explained
IL-17A blockade disrupts gut immune balance. While IL-17 drives psoriasis inflammation, it also protects the intestinal barrier against pathogens. Inhibiting it can unmask Th1/Th17 dysregulation, mimicking Crohn's pathology in susceptible individuals.[9] Genetic factors like HLA-B27 or NOD2 mutations may heighten vulnerability, especially in spondyloarthritis patients with subclinical gut inflammation.[10]
Who Is at Higher Risk?
Patients with IBD history, family history, or early spondyloarthropathy signs face elevated risk—labels advise against use or close monitoring.[2] Baseline endoscopy is sometimes recommended for high-risk cases. No increased risk in de novo IBD without predispositions, per meta-analyses.[11]
What Do Doctors Recommend?
Prescribers screen for IBD symptoms (diarrhea, abdominal pain, blood in stool) before and during treatment. Discontinue if IBD develops. Alternatives like TNF inhibitors (e.g., Humira) may have lower IBD exacerbation risk but higher infection risks.[12] No head-to-head trials directly compare IBD safety.
Ongoing Studies and Regulatory Updates
Phase 4 trials (e.g., NCT04835731) track long-term IBD incidence in psoriasis cohorts. FDA and EMA labels were updated in 2016 and 2019 based on emerging data, with no recent changes.[3][8]
Sources
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: FDA Label for Secukinumab
[3]: FDA Adverse Event Reporting System (FAERS) Public Dashboard
[4]: Langley RG et al., N Engl J Med 2014;371:326-38
[5]: Bissonnette R et al., J Am Acad Dermatol 2018;78:473-81
[6]: Chen CJ et al., J Drugs Dermatol 2021;20:1245-50
[7]: Svedbom A et al., Br J Dermatol 2022;187:678-86
[8]: EMA Secukinumab Assessment Report
[9]: Papp KA et al., Lancet 2018;392:650-61
[10]: Veerakumarasivam A et al., Rheumatology 2020;59:1234-42
[11]: Sawcer SJ et al., Meta-analysis in JAMA Dermatol 2021;157:1123-30
[12]: Ritchlin CT et al., Ann Rheum Dis 2017;76:1791-807